Published in Radiology on October 01, 2007
Neuroimaging of Parkinson's disease: Expanding views. Neurosci Biobehav Rev (2015) 0.87
Novel avenues of drug discovery and biomarkers for diabetes mellitus. J Clin Pharmacol (2010) 0.86
2-(2'-((Dimethylamino)methyl)-4'-(3-[(18)F]fluoropropoxy)-phenylthio)benzenamine for positron emission tomography imaging of serotonin transporters. Nucl Med Biol (2008) 0.84
Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine. PET Clin (2009) 0.82
Role of nuclear medicine in neuroHIV: PET, SPECT, and beyond. Nucl Med Commun (2014) 0.81
Multimodality molecular imaging of stem cells therapy for stroke. Biomed Res Int (2013) 0.78
Improving (18)F-Fluoro-D-Glucose-Positron Emission Tomography/Computed Tomography Imaging in Alzheimer's Disease Studies. World J Nucl Med (2015) 0.77
Brain and disease: the long path to discovery and treatment. Clin Pharmacol Ther (2009) 0.75
Qualitative and Quantitative Evaluation of Blob-Based Time-of-Flight PET Image Reconstruction in Hybrid Brain PET/MR Imaging. Mol Imaging Biol (2015) 0.75
Magnetic resonance microscopy. Anal Cell Pathol (Amst) (2012) 0.75
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med (2006) 7.40
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
Performance evaluation of the GE healthcare eXplore VISTA dual-ring small-animal PET scanner. J Nucl Med (2006) 2.98
Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med (2008) 2.93
Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med (2006) 2.87
Autoimmune hypophysitis. Endocr Rev (2005) 2.86
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol (2009) 2.67
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun (2004) 2.29
Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol (2009) 2.20
Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother (2009) 2.18
Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res (2005) 2.10
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem (2008) 2.03
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res (2009) 2.03
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res (2005) 1.97
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis (2011) 1.96
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol (2015) 1.90
NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov (2005) 1.89
The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery (2007) 1.89
Ecstasy and agony: activation of the human amygdala in positive and negative emotion. Psychol Sci (2002) 1.89
Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nat Med (2010) 1.81
Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem (2008) 1.79
Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology (2003) 1.77
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res (2011) 1.69
Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil. Proc Natl Acad Sci U S A (2005) 1.65
A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol (2004) 1.56
In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla. Magn Reson Med (2007) 1.55
68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem (2010) 1.51
Brain white matter anatomy of tumor patients evaluated with diffusion tensor imaging. Ann Neurol (2002) 1.46
ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res (2007) 1.45
Astroblastoma: radiologic-pathologic correlation and distinction from ependymoma. AJNR Am J Neuroradiol (2002) 1.44
Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med (2009) 1.44
Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. J Magn Reson Imaging (2013) 1.43
PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem (2013) 1.42
Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem (2008) 1.39
Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med (2008) 1.37
Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One (2009) 1.37
A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun (2009) 1.36
Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A (2003) 1.34
Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res (2010) 1.32
Dissociable neural pathways are involved in the recognition of emotion in static and dynamic facial expressions. Neuroimage (2003) 1.31
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw (2007) 1.26
Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer. PLoS One (2012) 1.25
Diffusion tensor MR imaging of the brain and white matter tractography. AJR Am J Roentgenol (2002) 1.24
Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol (2005) 1.23
Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst (2010) 1.22
Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med (2009) 1.19
Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed Engl (2011) 1.18
The functional anatomy of parkinsonian bradykinesia. Neuroimage (2003) 1.18
Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther (2008) 1.18
A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. J Magn Reson Imaging (2005) 1.17
Molecular imaging techniques in body imaging. Radiology (2007) 1.16
Dual magnetic-/temperature-responsive nanoparticles for microfluidic separations and assays. Langmuir (2007) 1.16
Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. PLoS One (2007) 1.15
Transforming thymidine into a magnetic resonance imaging probe for monitoring gene expression. J Am Chem Soc (2013) 1.15
Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study. Magn Reson Imaging (2010) 1.14
Spatio-temporal modification of collagen scaffolds mediated by triple helical propensity. Biomacromolecules (2008) 1.13
Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biol Psychiatry (2004) 1.13
Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med (2003) 1.13
NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol (2009) 1.12
Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med (2011) 1.11
Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. Alzheimers Dement (2007) 1.10
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther (2009) 1.10
Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood-brain barrier through paracellular transmigration and ERK activation. J Neuroinflammation (2012) 1.09
Virus-associated tumor imaging by induction of viral gene expression. Clin Cancer Res (2007) 1.06
Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer. Mol Imaging (2007) 1.04
Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry (2003) 1.04
Cocaine-induced brain activation determined by positron emission tomography neuroimaging in conscious rhesus monkeys. Psychopharmacology (Berl) (2001) 1.03
Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay. Cancer Res (2009) 1.02
Clinical applications of Gallium-68. Appl Radiat Isot (2013) 1.02
Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia (2009) 1.02
A positron emission tomography study of methylphenidate in adults with ADHD: alterations in resting blood flow and predicting treatment response. Neuropsychopharmacology (2003) 1.02
Measurement of dopamine transporter occupancy for multiple injections of cocaine using a single injection of [F-18]FECNT. Synapse (2002) 1.02
Estimating myocardial perfusion from dynamic contrast-enhanced CMR with a model-independent deconvolution method. J Cardiovasc Magn Reson (2008) 1.01
Targeting collagen strands by photo-triggered triple-helix hybridization. Proc Natl Acad Sci U S A (2012) 1.01
Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett (2009) 1.00
Magnetic resonance imaging features of pituicytomas: analysis of 10 cases. J Comput Assist Tomogr (2010) 0.99
Methodology for quantitative rapid multi-tracer PET tumor characterizations. Theranostics (2013) 0.98
Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography. Neurosci Lett (2005) 0.98
Dysregulation of glutamate carboxypeptidase II in psychiatric disease. Schizophr Res (2008) 0.97
Evaluation of human brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches. Magn Reson Med (2008) 0.97
Tuning phenols with Intra-Molecular bond Shifted HYdrogens (IM-SHY) as diaCEST MRI contrast agents. Chemistry (2014) 0.97
The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging. AJR Am J Roentgenol (2003) 0.96
Shape-memory surface with dynamically tunable nano-geometry activated by body heat. Adv Mater (2011) 0.96
New agents and techniques for imaging prostate cancer. J Nucl Med (2009) 0.96
Meeting report: high-throughput technologies for in vivo imaging agents. Mol Imaging (2005) 0.96
Synthesis of [(125)I]iodoDPA-713: a new probe for imaging inflammation. Biochem Biophys Res Commun (2009) 0.96
An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer. Clin Cancer Res (2008) 0.96
Subcortical dopaminergic deficits in a DISC1 mutant model: a study in direct reference to human molecular brain imaging. Hum Mol Genet (2013) 0.95
Molecular imaging: integration of molecular imaging into the musculoskeletal imaging practice. Radiology (2007) 0.95
⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem (2014) 0.94
CuInSe/ZnS core/shell NIR quantum dots for biomedical imaging. Small (2011) 0.94
Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells. Neoplasia (2009) 0.94
Molecular imaging of metastatic potential. J Nucl Med (2008) 0.94
Switchable surface traps for injectable bead-based chromatography in PDMS microfluidic channels. Lab Chip (2006) 0.94
Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjug Chem (2012) 0.93
Diagnostic accuracy using diffusion tensor imaging in the diagnosis of ALS: a meta-analysis. Acad Radiol (2012) 0.92
An imbalance between excitatory and inhibitory neurotransmitters in amyotrophic lateral sclerosis revealed by use of 3-T proton magnetic resonance spectroscopy. JAMA Neurol (2013) 0.92
A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). Oncotarget (2011) 0.92